TP63

Across TCGA pan-cancer cohorts, TP63 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TP63 data layer compared with 26 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher TP63 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TP63 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

LSCC, PDAC, and LUAD are the cancer types where TP63 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Quartile	II,III,IV	1.000	0.719	.009	5	view →
PDAC	OS	Median	III,IV	0.210	0.868	.038	5	view →
LUAD	OS	Median	All	0.934	0.552	.038	2	view →
HNSC	DFS	Median	IV	0.328	0.889	.014	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TP63–LSCC (DFS)

Open the LSCC breakdown →